Notizie AIOM – anno XIV n. 594

30 Agosto 2016

Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1

Cabozantinib is an inhibitor of kinases, including MET and vascular endothelial growth factor receptors, and has shown activity in men with previously treated metastatic castration-resistant prostate cancer (mCRPC). This blinded phase III trial compared cabozantinib with ...
Leggi tutto

29 Agosto 2016

Determinants of Patient-Oncologist Prognostic Discordance in Advanced Cancer

Patients with advanced cancer often report expectations for survival that differ from their oncologists’ expectations. Whether patients know that their survival expectations differ from those of their oncologists remains unknown. This distinction is important because ...
Leggi tutto

29 Agosto 2016

Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2

Phase I data (ASCEND-1) showed ceritinib efficacy in patients with ALK-rearranged non–small-cell lung cancer (NSCLC), regardless of brain metastases status and with or without prior therapy with an inhibitor of the ALK protein. Data are presented from a phase II trial ...
Leggi tutto

26 Agosto 2016

Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline

To develop recommendations about endocrine therapy for women with hormone receptor (HR) –positive metastatic breast cancer (MBC). The American Society of Clinical Oncology convened an Expert Panel to conduct a systematic review of evidence from 2008 through 2015 to ...
Leggi tutto

26 Agosto 2016

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

Approximately 75% of objective responses to anti–programmed death 1 (PD-1) therapy in patients with melanoma are durable, lasting for years, but delayed relapses have been noted long after initial objective tumor regression despite continuous therapy. Mechanisms of ...
Leggi tutto

26 Agosto 2016

16 agosto 2016 – AIFA al Meeting di Rimini 2016 “La salute è un bene comune, difendiamolo insieme”

26 Agosto 2016

La Commissione Europea approva pembrolizumab per il trattamento del NSCLC positivo a PD-L1

The European Commission (EC) has approved pembrolizumab (Keytruda) as a treatment for patients with locally advanced or metastatic PD-L1–positive non–small cell lung cancer (NSCLC) following at least 1 chemotherapy regimen, according to Merck, the manufacturer ...
Leggi tutto

26 Agosto 2016

Opinione favorevole del CHMP per crizotinib nel NSCLC positivo a ROS1

The Committee for Medicinal Products for Human Use (CHMP) has adopted a positive option for crizotinib as a treatment for adults with ROS1-positive advanced non–small cell lung cancer (NSCLC), suggesting an approval may be imminent. The positive opinion was based on ...
Leggi tutto

26 Agosto 2016

ASCO and SGO Release Clinical Practice Guideline on Neoadjuvant Therapy for Newly Diagnosed Advanced Ovarian Cancer

As reported by Alexi A. Wright, MD, MPH, of Dana-Farber Cancer Institute, and colleagues in the Journal of Clinical Oncology, ASCO and the Society of Gynecologic Oncology (SGO) have released a clinical practice guideline on neoadjuvant therapy for patients with newly diagnosed ...
Leggi tutto

26 Agosto 2016

ASCO and SGO Issue New Guideline on Ovarian Cancer Treatment

ASCO and the Society of Gynecologic Oncology (SGO) today issued a joint clinical practice guideline on ovarian cancer treatment. The guideline provides evidence-based recommendations on whether to use neoadjuvant chemotherapy or surgery as the initial treatment for women ...
Leggi tutto

LAVORIAMO CON

News

TUMORE DEL SENO: 7 DONNE SU 10 COLPITE ANCHE DA VAMPATE DI CALORE. ‘NUOVA TERAPIA ORALE PUO’ CONTRASTARLE E FAVORIRE ADERENZA ALLE CURE’

FENILCHETONURIA: ITALIA RILEVANTE IN EUROPA PER INCIDENZA. “SCREENING NEONATALE PREVIENE DANNI NEUROLOGICI, MA NECESSARIA CONTINUITÀ DI CURA”

BRISTOL MYERS SQUIBB: “DA 80 ANNI IN ITALIA PORTIAMO INNOVAZIONE AI PAZIENTI”. IL LIVE PAINTING A PALAZZO MERULANA DISEGNA IL PONTE FRA ARTE E SCIENZA

LEUCEMIA LINFATICA CRONICA: L’ARTE DÀ VOCE ALL’ESPERIENZA DEI PAZIENTI. BEONE MEDICINES SOSTIENE IL PROGETTO DI PREGONI ALLA 61° BIENNALE D’ARTE DI VENEZIA

TUMORI PROSTATA: IN ITALIA 485MILA UOMINI VIVONO CON LA MALATTIA. SIUrO ED EUROPA UOMO ITALIA PRESENTANO LA “CARTA DELLE DOMANDE”

FOSSC: “BENE FINALMENTE L’ARRIVO DEI NUOVI LIVELLI ESSENZIALI D’ASSISTENZA DOPO BEN 9 ANNI DI ATTESA MA ORA SERVE CON RAPIDITA’ UN ULTERIORE AGGIORNAMENTO PER COPRIRE GLI ULTIMI 3 ANNI DI ACQUISIZIONE DI TRATTAMENTI INNOVATIVI”

MIASTENIA GRAVIS: IN ITALIA COLPITI PIU’ DI 15MILA UOMINI E DONNE. GLI ESPERTI, “PRIORITA’ LA PERSONALIZZAZIONE DELLE TERAPIE”

Notizie AIOM – anno XIV n. 594

Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1

Determinants of Patient-Oncologist Prognostic Discordance in Advanced Cancer

Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2

Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

16 agosto 2016 – AIFA al Meeting di Rimini 2016 “La salute è un bene comune, difendiamolo insieme”

La Commissione Europea approva pembrolizumab per il trattamento del NSCLC positivo a PD-L1

Opinione favorevole del CHMP per crizotinib nel NSCLC positivo a ROS1

ASCO and SGO Release Clinical Practice Guideline on Neoadjuvant Therapy for Newly Diagnosed Advanced Ovarian Cancer

ASCO and SGO Issue New Guideline on Ovarian Cancer Treatment